Scarica l'app Stockscreener
0.2235
5.20%
0.0111
Dopo l'orario di chiusura:
.23
0.0065
+2.91%
Precedente Chiudi:
$0.2125
Aprire:
$0.2125
Volume 24 ore:
157.01K
Relative Volume:
0.06
Capitalizzazione di mercato:
$3.09M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-16.98%
1M Prestazione:
-39.43%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.2125
$0.23
Intervallo di 1 settimana:
$0.207
$0.2712
Portata 52W:
$0.207
$2.57
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Nome
Silexion Therapeutics Corp
Settore
Industria
Telefono
972-8-6286005
Indirizzo
12 ABBA HILLEL ROAD, RAMAT GAN
Confronta SLXN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| SLXN | 0.2235 | 3.09M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Silexion Therapeutics Corp Borsa (SLXN) Ultime notizie
SLXN Stock Plummets to 52-Week Low at $0.23 Amid Market Turbulence - Investing.com India
Silexion Therapeutics Reports Q3 2024 Financial Results and Clinical Progress - Citybuzz
SLXN stock touches 52-week low at $0.27 amid market challenges - Investing.com Canada
SLXN stock touches 52-week low at $0.27 amid market challenges By Investing.com - Investing.com South Africa
Silexion Therapeutics initiated with a Buy at Maxim - TipRanks
Form 424B3 Silexion Therapeutics - StreetInsider.com
Silexion Therapeutics Corp (SLXN) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Stock Market Recap: Silexion Therapeutics Corp (SLXN) Concludes at 0.29, a -8.91 Surge/Decline - The Dwinnex
Silexion Therapeutics to Participate in 2024 Maxim Healthcare Virtual Summit - Vancity Buzz
SLXN stock touches 52-week low at $0.4 amid market challenges By Investing.com - Investing.com South Africa
SLXN stock touches 52-week low at $0.4 amid market challenges - Investing.com Australia
Check Out Silexion Therapeutics Corp (SLXN)’s Trade Data Rather Than the Analysts’ Views - SETE News
Post-Trade Analysis: Silexion Therapeutics Corp (SLXN) Slides -13.65, Closing at 0.46 - The Dwinnex
Silexion Therapeutics Corp: Weathering Stock Market Storms with 1.78M Market Cap - The InvestChronicle
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
Take off with Silexion Therapeutics Corp (SLXN): Get ready for trading - SETE News
Market Update: Silexion Therapeutics Corp (SLXN) Sees Positive Movement, Closing at 0.56 - The Dwinnex
PetVivo (OTCQB: PETV) Revolutionizes Veterinary Medicine, - openPR
Omeros (OMER) Shares Drop 5.04% Amid Financial Struggles - GuruFocus.com
MRVI Stock Drops 5.11% Amid Financial Report Release - GuruFocus.com
Silexion Therapeutics Corp (SLXN) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Drones and biotechs are moving this morning 🛫 - RagingBull
siRNA candidate shows promise in preclinical studies - Investing.com
Silexion Therapeutics Unveils Promising Preclinical Data - openPR
siRNA candidate shows promise in preclinical studies By Investing.com - Investing.com UK
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies - Yahoo Finance
SLXN stock touches 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa
SLXN stock touches 52-week low at $0.55 amid market challenges - Investing.com Australia
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise - MSN
A new trading data show Silexion Therapeutics Corp (SLXN) is showing positive returns. - SETE News
In the Green: Silexion Therapeutics Corp (SLXN) Closes at 0.64, Up/Down -16.28 from Previous Day - The Dwinnex
SLXN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year - Benzinga
Diabetic Kidney Disease Market Revenue to Expand Significantly - openPR
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment - openPR
Silexion reports improved outcomes in pancreatic cancer trial - Investing.com
Silexion Therapeutics announces new findings from Loder trial - TipRanks
Stanrose Mafatlal Investments and Finance Limited (STANROS.BO) Latest Stock News & Headlines - Yahoo Finance
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer - Business Wire
Silexion Therapeutics sees board member resignation - Investing.com
Silexion Therapeutics sees board member resignation By Investing.com - Investing.com UK
Silexion Therapeutics Corp Announces Resignation of Ilan Shiloah as Independent Director, Member of Audit Committee, the Compensation Committee, and the Corporate Governance and Nominating Committee - Marketscreener.com
Emerging Precision Oncology Companies Show Promise Following Summit’s Success - Vancity Buzz
Industry Update: 3 Exciting Precision Oncology Players to Watch - openPR
'We've run out of money' says bar owner as venue closes after nine months - Liverpool Echo
Symbotic (NASDAQ:SYM) Shares Gap Up to $22.41 - Defense World
Australia's Sims tops benchmark gains on positive FY25 start - XM
The Potential Rise in the Price of Symbotic Inc (SYM) following insiders activity - Knox Daily
Symbotic (NASDAQ:SYM) Stock Price Up 4.9% - Defense World
Supply@ME Capital (LON:SYME) Sets New 1-Year Low at $0.01 - Defense World
Silexion Therapeutics Corp Azioni (SLXN) Dati Finanziari
Non sono disponibili dati finanziari per Silexion Therapeutics Corp (SLXN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):